Nasdaq:KRYS

PITTSBURGH, July 26, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company focused on the discovery, development and…

<!-- Name:DistributionId Value:8843111 --> <!-- Name:EnableQuoteCarouselOnPnr Value:False -->…

PITTSBURGH, Jan. 18, 2023 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a biotechnology company focused on developing and commercializing genetic medicines for…

PITTSBURGH, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) a biotechnology company focused on developing and commercializing genetic medicines for…

• La Société est sur la bonne voie pour soumettre sa demande de mise sur le marché européen au 4e trimestre 2022 • Aucune étude supplémentaire n'est requise PITTSBURGH, 23 sept. 2022…

• Das Unternehmen befindet sich im Zeitplan, um im vierten Quartal 2022 einen Zulassungsantrag für Europa zu stellen • Es sind keine weiteren Studien erforderlich PITTSBURGH,…

• Company on track to submit European marketing application in Q4 2022 • No additional studies required PITTSBURGH, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the…

FDA granted Priority Review designationPDUFA target action date is February 17, 2023FDA stated that it is not currently planning to hold an advisory committee meeting PITTSBURGH, Aug.…

KB407 is an investigational, redosable gene therapy candidate designed to treat all patients with cystic fibrosis regardless of the underlying genetic mutation PITTSBURGH, Aug. 01, 2022…

Treatment with B-VEC demonstrated robust functional COL7 expression followed by its assembly into basement membrane-associated anchoring fibrils Treatment with B-VEC improved durable wound…